27-May-22
22-Jun-21
Spot the difference. There's only 2 reasons they would remove FTO expression status as an endpoint:
1. They think Zantrene is validated as an FTO inhibitor.
2. The opposite.
Either way, doesn't look like they wanted to leave this to an investigator-led trial to report. I imagine they will want to announce this data (if validating) off the back of their own work, validated by Sheba.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.015(1.22%) |
Mkt cap ! $215.4M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.23 | $106.2K | 85.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 11900 | $1.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 819 | 1 |
View Market Depth
| Last trade - 15.56pm 26/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |